Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer
ConditionOligometastatic Prostate Carcinoma
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-75
SponsorChanghai Hospital
About this trial
The optimal treatment for oligometastatic prostate cancer (OMPC) is still on its way. Accumulating evidence has proven the safety and feasibility of radical prostatectomy and local or metastasis-directed radiotherapy for oligometastatic patients. The aim of this trial is to compare the safety and feasibility outcomes of metastasis-directed neoadjuvant radiotherapy (naRT) and neoadjuvant androgen deprivation therapy (naADT) followed by robotic-assisted radical prostatectomy (RARP) to ADT combined with abiraterone for treating OMPC.
Eligibility criteria
Qualifiers
Histologically confirmed adenocarcinoma of the prostate without small cell features
Oligometastatic PCa assessed by Ga-68 prostate-specific membrane antigen (PSMA), PET/CT
<4 bone oligometastases, lymph node metastasis below the renal artery level
Expected survival time >5 years
Disqualifiers
Any previous or ongoing treatment for PCa, including radiotherapy, ADT, chemotherapy, focal treatment, etc.
Patients who have previously undergone transurethral resection or enucleation of the prostate.
Patients who have undergone other abdominal surgery within the last 3 months
Patients who have visceral metastases
Trial design
Treatments tested in this trial
- ADT combined with abiraterone
- neoadjuvant hormone and RT
Treatment groups
200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov